[
  {
    "ts": null,
    "headline": "Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now",
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
    "url": "https://finnhub.io/api/news?id=457d6e9ea64b00b301110001559827e9fa76288ef301adb631cc8dac47b0f55e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770655505,
      "headline": "Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now",
      "id": 138693766,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
      "url": "https://finnhub.io/api/news?id=457d6e9ea64b00b301110001559827e9fa76288ef301adb631cc8dac47b0f55e"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?",
    "summary": "Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.",
    "url": "https://finnhub.io/api/news?id=41405dd86b09ed0279733ecbeca2fcb29dcd59a3254409eb2027a4744c51d62a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770655080,
      "headline": "Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?",
      "id": 138693763,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.",
      "url": "https://finnhub.io/api/news?id=41405dd86b09ed0279733ecbeca2fcb29dcd59a3254409eb2027a4744c51d62a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Buy Cell Therapy Company Orna for $2.4 Billion",
    "summary": "Eli Lilly  shares rose Monday after the Mounjaro maker said it had agreed to acquire biotechnology company Orna Therapeutics for $2.4 billion in cash.  The deal value comprises an upfront payment and subsequent payments upon the achievement of clinical development milestones, Lilly said on Monday.  Orna Therapeutics develops RNA drugs targeting cancers, genetic disorders, and other chronic conditions.",
    "url": "https://finnhub.io/api/news?id=02bac86869c1d41106201ab84b6bdd9f41e989480cf0ce97807b8d661111a0bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770653100,
      "headline": "Eli Lilly to Buy Cell Therapy Company Orna for $2.4 Billion",
      "id": 138608836,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Eli Lilly  shares rose Monday after the Mounjaro maker said it had agreed to acquire biotechnology company Orna Therapeutics for $2.4 billion in cash.  The deal value comprises an upfront payment and subsequent payments upon the achievement of clinical development milestones, Lilly said on Monday.  Orna Therapeutics develops RNA drugs targeting cancers, genetic disorders, and other chronic conditions.",
      "url": "https://finnhub.io/api/news?id=02bac86869c1d41106201ab84b6bdd9f41e989480cf0ce97807b8d661111a0bf"
    }
  },
  {
    "ts": null,
    "headline": "Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica",
    "summary": "Growth is fueled by the adoption of advanced analytics platforms, AI-driven modules, and cloud-based solutions that optimize drug discovery, clinical trials, pharmacovigilance, and precision medicine. Leading players such as Roche, Johnson & Johnson, AstraZeneca, and Merck are investing heavily in specialized analytics tools and dedicated data teams to accelerate real-time decision-making, improve patient stratification, and enhance treatment outcomes.Chicago, Feb. 09, 2026 (GLOBE NEWSWIRE) -- T",
    "url": "https://finnhub.io/api/news?id=607f9f05b9b9a2daf0dc496291a7821389a2c7a302ce425ec42c736ae4d06a7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770652260,
      "headline": "Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica",
      "id": 138514559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Growth is fueled by the adoption of advanced analytics platforms, AI-driven modules, and cloud-based solutions that optimize drug discovery, clinical trials, pharmacovigilance, and precision medicine. Leading players such as Roche, Johnson & Johnson, AstraZeneca, and Merck are investing heavily in specialized analytics tools and dedicated data teams to accelerate real-time decision-making, improve patient stratification, and enhance treatment outcomes.Chicago, Feb. 09, 2026 (GLOBE NEWSWIRE) -- T",
      "url": "https://finnhub.io/api/news?id=607f9f05b9b9a2daf0dc496291a7821389a2c7a302ce425ec42c736ae4d06a7a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Rises. It’s Acquiring This Cell Therapy Company for $2.4 Billion.",
    "summary": "Eli Lilly  shares rose after the Mounjaro maker said it had agreed to acquire biotechnology company Orna Therapeutics for $2.4 billion in cash.  The deal value comprises an upfront payment and subsequent payments upon the achievement of clinical development milestones, Lilly said.  Orna Therapeutics develops RNA drugs targeting cancers, genetic disorders, and other chronic conditions.",
    "url": "https://finnhub.io/api/news?id=897fc7d1fc2a9b5c1b358911fb66a1c7888a8001934d5d637a7e4674e940d399",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770640440,
      "headline": "Eli Lilly Stock Rises. It’s Acquiring This Cell Therapy Company for $2.4 Billion.",
      "id": 138414694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Eli Lilly  shares rose after the Mounjaro maker said it had agreed to acquire biotechnology company Orna Therapeutics for $2.4 billion in cash.  The deal value comprises an upfront payment and subsequent payments upon the achievement of clinical development milestones, Lilly said.  Orna Therapeutics develops RNA drugs targeting cancers, genetic disorders, and other chronic conditions.",
      "url": "https://finnhub.io/api/news?id=897fc7d1fc2a9b5c1b358911fb66a1c7888a8001934d5d637a7e4674e940d399"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones' revolving door: What happened to 5 companies after that were dropped from the DJIA",
    "summary": "The Dow Jones Industrial Average (DJIA) is the oldest stock index in America. Founded in 1896 by Charles Dow, Edward Jones, and Charles Bergstresser, it’s considered a benchmark for the performance of the country’s large, blue-chip companies—those big household names, like Home Depot (HD), Johnson ...",
    "url": "https://finnhub.io/api/news?id=5fbd7c7548eb9039b617ca6f87393d56bb2cdfbc161029ece3d8ab972c685b53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770648780,
      "headline": "Dow Jones' revolving door: What happened to 5 companies after that were dropped from the DJIA",
      "id": 138514561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average (DJIA) is the oldest stock index in America. Founded in 1896 by Charles Dow, Edward Jones, and Charles Bergstresser, it’s considered a benchmark for the performance of the country’s large, blue-chip companies—those big household names, like Home Depot (HD), Johnson ...",
      "url": "https://finnhub.io/api/news?id=5fbd7c7548eb9039b617ca6f87393d56bb2cdfbc161029ece3d8ab972c685b53"
    }
  },
  {
    "ts": null,
    "headline": "J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent Loss",
    "summary": "JNJ's Innovative Medicine unit grew sales 4.1% in 2025 despite Stelara'sZER LOE, topping $60B as Darzalex and new drugs offset pressure",
    "url": "https://finnhub.io/api/news?id=607347dec3f1bbb23856464cc50ee4d2270338b62616b19102569ae87a2c96a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770647040,
      "headline": "J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent Loss",
      "id": 138608841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ's Innovative Medicine unit grew sales 4.1% in 2025 despite Stelara'sZER LOE, topping $60B as Darzalex and new drugs offset pressure",
      "url": "https://finnhub.io/api/news?id=607347dec3f1bbb23856464cc50ee4d2270338b62616b19102569ae87a2c96a0"
    }
  },
  {
    "ts": null,
    "headline": "Banking on Yield? Here’s How We Scored Dime Community Bancshares (DCOM) Dividend",
    "summary": "Regional banks continued their steady dividend payouts this week, with Dime Community Bancshares (NASDAQ: DCOM) paying 25 cents per share on Jan. 23, maintaining the quarterly rate it’s held since early 2023. The payment reflects a 2.79% dividend yield based on the current stock price of $36.23, but the real story lies in whether these ... Banking on Yield? Here’s How We Scored Dime Community Bancshares (DCOM) Dividend",
    "url": "https://finnhub.io/api/news?id=1a8f7c7914ac065bae8eba512a4bc1d70baced05f17de6775dc42a5963366530",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770645080,
      "headline": "Banking on Yield? Here’s How We Scored Dime Community Bancshares (DCOM) Dividend",
      "id": 138514562,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Regional banks continued their steady dividend payouts this week, with Dime Community Bancshares (NASDAQ: DCOM) paying 25 cents per share on Jan. 23, maintaining the quarterly rate it’s held since early 2023. The payment reflects a 2.79% dividend yield based on the current stock price of $36.23, but the real story lies in whether these ... Banking on Yield? Here’s How We Scored Dime Community Bancshares (DCOM) Dividend",
      "url": "https://finnhub.io/api/news?id=1a8f7c7914ac065bae8eba512a4bc1d70baced05f17de6775dc42a5963366530"
    }
  },
  {
    "ts": null,
    "headline": "Can reshoring deliver manufacturing sustainability benefits?",
    "summary": "Manufacturers may be weighing tariff costs, but they’re also assessing whether domestic production investments can help achieve supply chain resilience, procurement and labor goals.",
    "url": "https://finnhub.io/api/news?id=263974c37ecc892c81f8c7acfe34715c59bbb69dee0c975988f974e4867170dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770629220,
      "headline": "Can reshoring deliver manufacturing sustainability benefits?",
      "id": 138514287,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Manufacturers may be weighing tariff costs, but they’re also assessing whether domestic production investments can help achieve supply chain resilience, procurement and labor goals.",
      "url": "https://finnhub.io/api/news?id=263974c37ecc892c81f8c7acfe34715c59bbb69dee0c975988f974e4867170dc"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Reports 90% AFib Freedom In Early Heart Device Study",
    "summary": "Johnson &amp; Johnson shared early AFib study results showing 90% success and no safety issues, but the stock lagged as healthcare stocks outperformed broader markets.",
    "url": "https://finnhub.io/api/news?id=1563532e57505fba147400372034b9fa8b6eddb4abe40083800b1c6b49b1ae4c",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770625510,
      "headline": "Johnson & Johnson Reports 90% AFib Freedom In Early Heart Device Study",
      "id": 138563866,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/09/Johnson--Johnson-Inc--JNJ.jpeg?width=2048&height=1536",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": "Johnson &amp; Johnson shared early AFib study results showing 90% success and no safety issues, but the stock lagged as healthcare stocks outperformed broader markets.",
      "url": "https://finnhub.io/api/news?id=1563532e57505fba147400372034b9fa8b6eddb4abe40083800b1c6b49b1ae4c"
    }
  },
  {
    "ts": null,
    "headline": "Reported Friday, Johnson & Johnson Highlighted OMNYPULSE OMNY-AF Pilot Results And VARIPULSE Data Reinforcing Favorable Safety And Efficiency Profile At 2026 AF Symposium In Boston",
    "summary": "OMNY-AF pilot study reports 90% 12-month freedom from AFib with zero procedure-related adverse eventsiAdditional data presented further reinforces the favorable and consistent safety and efficiency profile of the",
    "url": "https://finnhub.io/api/news?id=b864345dd2259f84bd1e2586cb628aad15632df2d9feaf046b3f8f51274b65ef",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770611988,
      "headline": "Reported Friday, Johnson & Johnson Highlighted OMNYPULSE OMNY-AF Pilot Results And VARIPULSE Data Reinforcing Favorable Safety And Efficiency Profile At 2026 AF Symposium In Boston",
      "id": 138563867,
      "image": "",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": "OMNY-AF pilot study reports 90% 12-month freedom from AFib with zero procedure-related adverse eventsiAdditional data presented further reinforces the favorable and consistent safety and efficiency profile of the",
      "url": "https://finnhub.io/api/news?id=b864345dd2259f84bd1e2586cb628aad15632df2d9feaf046b3f8f51274b65ef"
    }
  }
]